左西替利嗪杂质20 | 83881-53-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 左西替利嗪杂质20
• 英文名称: 2-[2-[4-(diphenylmethyl)-1-piperazinyl]ethoxy]-acetic acid
• 英文别名: Deschlorocetirizine；2-[2-(4-benzhydrylpiperazin-1-yl)ethoxy]acetic acid
• CAS: 83881-53-2
• 化学式: C₂₁H₂₆N₂O₃
• 分子量: 354.449
• InChiKey: PCSREFRBRMMIHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  53
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Processes for the Synthesis of Levocetirizine and Intermediates for Use Therein
  申请人：Rao Dharmaraj Ramachandra

  公开号：US20110184174A1

  公开（公告）日：2011-07-28

  The present invention provides a compound of formula (IV) wherein R is Cl, Br, NO 2 , OH or OR′, and R′ is alkyl, and its use in the synthesis of levocetirizine, including its use in the synthesis of (−)-1-[(4-chlorophenyl)-phenylmethyl]piperazine, an intermediate useful in the synthesis of levocetirizine. The present invention also provides compounds (II) and (III) which are useful in the synthesis of compound (IV).

  本发明提供了一种化合物，其化学式为(IV)，其中R为Cl、Br、NO2、OH或OR′，R′为烷基，并且其在左旋西替利嗪的合成中的应用，包括其在合成(−)-1-[(4-氯苯基)-苯甲基]哌嗪中的应用，这是左旋西替利嗪合成中有用的中间体。本发明还提供了化合物(II)和(III)，它们在化合物(IV)的合成中有用。
• Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
  申请人：Robinson B. Cynthia

  公开号：US20050026890A1

  公开（公告）日：2005-02-03

  A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising an antihistamine for the treatment of asthma, chronic obstructive pulmonary disease, or any other respiratory disease. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or any other respiratory disease.

  一种制药或兽医组合物，包括第一活性剂，所述第一活性剂选自去氢表雄酮和/或去氢表雄酮硫酸盐，或其盐，并且第二活性剂包括一种抗组胺药物，用于治疗哮喘、慢性阻塞性肺疾病或任何其他呼吸系统疾病。该组合物以各种制剂和套装形式提供。本专利的产品应用于哮喘、慢性阻塞性肺疾病或任何其他呼吸系统疾病的预防和治疗。
• NOVEL PROCESS FOR PREPARING HIGHLY PURE LEVOCETIRIZINE AND SALTS THEREOF
  申请人：Zelikovitch Lior

  公开号：US20110230496A1

  公开（公告）日：2011-09-22

  A process for preparing pure levocetirizine and salts thereof, e.g., the levocetirizine dihydrochloride, and a pharmaceutical composition comprising levocetirizine dihydrochloride produced by the process are disclosed.

  本发明公开了一种制备纯左西替利嗪及其盐，例如左西替利嗪二盐酸盐的方法，以及由该方法生产的含左西替利嗪二盐酸盐的药物组合物。
• NOVEL IMIDAZOLE DERIVATIVE, PHARMACEUTICAL USE THEREOF, AND INTERMEDIATE THEREFOR
  申请人：Kyoto Pharmaceutical Industries, Ltd.

  公开号：EP0597112A1

  公开（公告）日：1994-05-18

  An imidazole derivative represented by general formula (I), wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. A process for producing the derivative or salt, and a pharmaceutical use thereof, in particular, a prophylactic and/or therapeutic agent for diseases induced by thromboxane A₂ or histamine. A compound represented by genenral formula (II) or (IV), wherein each symbol is as defined in the specification. The imidazole derivative and the salt are useful as a prophylactic and/or therapeutic agent for diseases induced by thromboxane A₂ or histamine, and the compounds (II) and (IV) are novel.

  由通式(I)代表的咪唑衍生物，其中各符号如说明书中所定义，或其药学上可接受的盐。一种生产该衍生物或盐的工艺及其药物用途，特别是血栓素 A₂或组胺诱发疾病的预防和/或治疗剂。由属式（II）或（IV）代表的化合物，其中各符号如说明书中所定义。咪唑衍生物和盐可用作血栓素 A₂或组胺诱发疾病的预防剂和/或治疗剂，且化合物 (II) 和 (IV) 具有新颖性。
• Pharmaceutical compositions for the treatment of rhinitis
  申请人：——

  公开号：US20010020023A1

  公开（公告）日：2001-09-06

  A pharmaceutical composition comprising a therapeutically effective amount of a mixture consisting essentially of (i) pseudoephedrine, an individual optical isomer or a pharmaceutically acceptable salt thereof, and (ii) at least one compound selected from 2-[4-(diphenylmethyl)-1-piperazinyl]-acetic acid or amide derivatives, an individual optical isomer or a pharmaceutically acceptable salt thereof.

  一种药物组合物，含有治疗有效量的混合物，其主要成分为 (i) 伪麻黄碱、其单个光学异构体或药学上可接受的盐，和 (ii) 至少一种选自 2-[4-(二苯基甲基)-1-哌嗪基]-乙酸或酰胺衍生物的化合物、其单个光学异构体或药学上可接受的盐。